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Updates on the Diagnosis and Management of Hepatocellular
Carcinoma
Aimun Raees1, Muhammad Kamran2, Hasan Özkan3 , Wasim Jafri4

A b s t r ac t
Introduction: Globally, the incidence, as well as mortality, related to hepatocellular carcinoma (HCC) is on the rise, owing to relatively few
curative options. Underlying cirrhosis is the most common etiology leading to HCC, but risk factors of cirrhosis show great regional variability.
Over the years, there has been a steady development in the diagnostic and therapeutic modalities of HCC, including the availability of a wide
range of systemic chemotherapeutic agents. We aim to review the recent advancements in the diagnostic and therapeutic strategies for HCC.
Methodology: The literature search was done using databases PubMed, Cochrane, and Science Direct, and the latest relevant articles were
reviewed.
Findings: Screening of HCC is a pivotal step in the early diagnosis of the disease. Current guidelines recommend using ultrasound and alfa
fetoprotein but various new biomarkers are under active research that might aid in diagnosing very small tumors, not picked up by the current
screening methods. Treatment options are decided based upon the overall performance of the patient and the extent of the disease, as per the
Barcelona classification. There are very few options that offer a cure for the disease, ranging from liver resection and transplantation to tumor
ablation. Downstaging has proven to have a significant role in the course of the disease. An attempt to control the disease can be made via
radiological interventions, such as transarterial chemoembolization, transarterial radioembolization, or radiation therapy. For advanced disease,
sorafenib used to be the only option until a couple of years ago. Recently, many other systemic agents have received approval as first-line and
second-line therapies for HCC. Genomics is an area of active clinical research as understanding the mutations and genomics involved in the
evolution of HCC might lead to a breakthrough therapy.
Keywords: Contrast-enhanced ultrasound, Genomics, Hepatocellular carcinoma, Immune checkpoint inhibitors, Lenvatinib, Metabolomics,
Microwave ablation, Nivolumab, Transarterial radioembolization.
Euroasian Journal of Hepato-Gastroenterology (2021): 10.5005/jp-journals-10018-1335

Introduction
Hepatocellular carcinoma (HCC) is one of the most lethal cancers
as its incidence has been on the rise for the past 10 years, making
it the sixth most commonly diagnosed cancer worldwide and
the fourth leading cause of cancer-related deaths annually.1
In 2018, the total number of new HCC cases globally was
approximately 670,000, with 625,000 HCC related deaths. 2 It
is the most common primary liver neoplasm with cirrhosis
being the main underlying etiology. The risk factors of cirrhosis
are significantly variable. Chronic hepatitis B virus (HBV) and
aflatoxin exposure are common risk factors for cirrhosis in Asia
and Africa3 whereas in developed countries like USA, Europe,
and Japan, chronic hepatitis C virus (HCV) along with alcoholic
and nonalcoholic liver disease are more frequently identified.4,5
The only effective way to reduce the risk of HCC is to promote a
healthy lifestyle along with adhering to the treatment of chronic
hepatitis. 6 Additionally, vaccination against HBV is another
crucial step towards eliminating the risk of development of
HCC. HCC is considered to have a poor prognosis because most
cases are usually subclinical at the early stages when potentially
curative treatment options are available and by the time of
detection, they have reached to an advanced stage with very
limited options of treatment remaining. This review article
aims to analyze the recent advancements in the diagnosis and
treatment of HCC and the available evidence to support the new
therapeutic modalities.
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Methods
PubMed, Cochrane, and Science Direct databases were searched
using keywords HCC, liver-directed therapies, systemic therapy, and
immunotherapy. Relevant information from peer-reviewed articles
was included. Appropriate reference articles were also retrieved.
Non-English articles and non-human studies were excluded.

Diagnosis
The aim of surveillance programs is to detect early tumors in patients
with a good prognosis profile. This reduces cancer-related morbidity
and mortality and increases survival rate, as curative treatments can
be readily offered at this point in time. Surveillance is recommended
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in all patients with cirrhosis irrespective of etiology. However, patients
having chronic HBV in the absence of underlying cirrhosis also require
regular surveillance, since HBV is an independent risk factor for HCC
with a yearly incidence of more than 0.2%.7 The average tumor
doubling time is 4 to 6 months; hence, most of the clinical guidelines
suggest 6 monthly surveillance in patients with cirrhosis. 8-10
Tumor markers add value to surveillance as they are non-invasive
yet objective evaluation tools. The recommended investigation
for surveillance is ultrasonography with or without serum alphafetoprotein (AFP) levels, as combination of the two modalities
amplifies the rate of detection of early HCC. Ultrasonography is widely
available, easily tolerated, and cost-effective with a sensitivity of 58 to
80% when performed by an expert.11-14 Having said that, AFP is only
80% specific in diagnosing HCC, and the operator and equipment
dependence of ultrasonography may raise false suspicions and add
to the overall cost.15 Moreover, AFP can be normal in about 40% of
patients with early disease16 while sensitivity of ultrasonography
falls to only 30% for tumors <2 cm tumors.17 This lead to the search
of other tumor markers such as lectin-bound alpha-fetoprotein
(AFP-L3), glypican 3, des-gamma carboxyprothrombin (DCP),
osteopontin, annexin A2, acylcarnitine, alpha-fucosidase, Dickkopf
1, and Golgi protein 73. These have been studied and proven to be
useful but none of these were superior in accuracy when compared
to AFP.18,19 According to a study, more than 35% of patients with
very early HCC have elevated levels of DCP,20 while another study
claims that combination of DCP with AFP significantly improves the
detection rate of HCC. The specificity of the DCP is 91% in contrast
to 70% for AFP; however, sensitivity is significantly low (41%). 21
AFP-L3 has been found to be remarkably specific for HCC and is
associated with more aggressive and infiltrative tumors.22 A recent
meta-analysis showed moderate accuracy of Dickkopf-1 for detecting
HCC.23 Abnormally expressed circular RNAs are novel biomarkers
being studied for detection of early HCC.24 A panel of seven microRNAs has shown high diagnostic accuracy in HBV-related HCC.25,26
A study done in Egypt demonstrated vascular endothelial growth
factor (VEGF) as a promising serum marker for HCC. 27 Besides
biochemical markers, a serological model called GALAD score has
also been introduced, which uses age, sex, and tumor markers for the
diagnosis of HCC. It has emerged as a beneficial tool in a few studies
but has not been externally validated so far.28
HCC is only cancer that requires only imaging to reach
a definitive diagnosis. Almost all guidelines recommend an
image-based diagnosis of HCC. On a background of liver cirrhosis,
a definite diagnosis of HCC can be made if characteristic features
such as arterial phase hyperenhancement while washout during
delayed venous phase is present in a triphasic imaging study.29,30
Either a contrast-enhanced computed tomography (CT) scan or
magnetic resonance imaging (MRI) can be done, as both have similar
diagnostic accuracy. The sensitivity and specificity of triphasic CT
scan are 81 and 93%, respectively, while that of MRI is 91 and 95%,
respectively. 31 Use of hepatobiliary contrast agents (gadoxetic
acid and gadobenate dimeglumine) in MRI can further enhance
sensitivity, but specificity may be lower than extracellular contrast
agents for small HCC.32,33 A major limitation of CT scan is the intense
exposure to radiation. Besides CT and MRI, contrast-enhanced
ultrasound (CEUS) has also proven to be highly sensitive for the
diagnosis of HCC.34,35 A recent multicenter prospective study and
a meta-analysis, both report excellent diagnostic accuracy and high
specificity of CEUS for the diagnosis of HCC.36 However, CEUS may be
unable to distinguish intrahepatic cholangiocarcinoma from HCC.

In 2011, a standardized system was first proposed for the
interpretation and reporting of liver lesions. This system, endorsed
by the American College of Radiology, is called Liver Image
Reporting and Data System (LI-RADS) which classifies liver lesions
into five categories based on contrast uptake and washout. It ranges
from LR-1 lesions that are definitely benign, to LR-5 lesions that are
conclusive of HCC. LI-RADS can be applied on CT, MRI, or CEUS. The
system was recently updated in 2018. 37 LI-RADS is also utilized for
the assessment and reporting of tumor response after treatment.
Quite often, atypical lesions are encountered that do not
exhibit specific vascular profile and thus cannot be characterized
via LI-RADS system. It is also essential to note that LI-RADS cannot
be applied if the liver is noncirrhotic. 38 In both of these cases,
a diagnostic biopsy becomes necessary. A false-negative rate of
biopsies is around 30% due to the poor yield of the sample; hence,
a negative biopsy is not adequate to rule out HCC.39 A group of
immunohistochemical stains including glutamine synthetase,
glypican-3, and heat shock protein40 should be requested as
it increases specificity to 100% while sensitivity may still be
suboptimal.41,39
Metabolomics is an evolving technology that involves
a detailed examination of metabolites in a biological sample, also
analyzing at the same time the variations in the metabolic profile
as a result of exposure to the disease or drug.42 There is growing
interest in the role of metabolomics in predicting early HCC, and
metabolomics studies have been carried out in common liver
disorders like alcoholic liver disease, cirrhosis, and nonalcoholic
fatty liver disease.43 It is expected that such studies may be useful
in decreasing the occurrence of HCC in at-risk population.

Staging
Prognostication of disease is critical before planning therapeutic
strategies for HCC. For this purpose, several staging systems
have been designed.44 The Barcelona Clinic Liver Cancer (BCLC)
system has been the most widely recognized and extensively
validated classification since its first publication in 1999. 45,46
It incorporates tumor burden, degree of liver dysfunction, and
patient’s performance status based on the Eastern Cooperative
Oncology Group (ECOG) for determination of cancer stage and
patient prognosis. It classifies patients into five stages starting from
0 (very early), A (early), B (intermediate), C (advanced) to D (terminal)
stage.47 Both EASL and AASLD recommend using the BCLC system
for HCC staging and prognostic assessment. Table 1 shows the latest
version of the BCLC staging system.
Table 1: The Barcelona Clinic Liver Cancer (BCLC) system for staging
of HCC
Liver function (CTP
Tumor burden
score)
Single lesion
<2 cm
Child-Pugh A
A (early)
Single or three
lesions <3 cm
B (intermediate) Multinodular
tumor
Child-Pugh A or B
C (advanced)
Portal
invasion/extrahepatic spread

ECOG
score

D (terminal)

3–4

Stage
0 (very early)

Extensive disease Child-Pugh C

0

1–2
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Treatment
While opting for therapeutic strategies, the main intention is
to improve quality of life. The modality of treatment is chosen
according to the clinical status of the patient based on the
BCLC system. HCC is a complex disease with diverse therapeutic
options available; hence, it is advised to refer HCC patients to
multidisciplinary care teams that include hepatologists, surgeons,
interventional radiologists, and oncologists to develop an effective
treatment strategy.

Curative Therapy
For patients with BCLC stage 0 to A, curative treatments can be
offered. Potential curative options include liver resection (LR),
liver transplant (LT), and ablation. Ablation can be done through
radiofrequency waves (RFA), microwave (MWA), cryotherapy, or
alcohol injection.

Liver Resection
In patients with very early stage HCC without portal hypertension
or high bilirubin, LR is the treatment of choice. Decompensated
cirrhosis and vascular invasion are contraindications to LR. The
proportion of patients who fulfill the criteria for resection is usually
5 to 10%. Potential complications can be liver failure, infection,
thrombosis, or bleeding. The rate of survival depends upon the
operator experience and disease status at the time of surgery,
but the 5-year overall survival (OS) is estimated to be around 25
to 69.5%.48,49 The main demerit is a high recurrence rate of HCC,
approximately 60 to 100%.50 No adjuvant or neoadjuvant therapies
have been approved yet to decrease the risk of recurrence after
resection. Laparoscopic surgery is a less invasive alternative to open
resection, with reduced chances of postprocedure complications
and similar outcomes as open surgery51,52 but trials are needed for
its validation. A randomized control trial that compared open LR
with laparoscopic surgery concluded that the laparoscopic method
was superior to open surgery in terms of safety with equivocal
oncological outcome. 53 According to a recent meta-analysis,
laparoscopic LR provides comparable survival rates as conventional
open approach.54

Liver Transplantation
Liver transplantation provides the best outcome to cirrhotic patients
with early HCC. Besides removing tumor tissue, it also has the added
benefit of simultaneously curing cirrhosis. As per EASL and AASLD
guidelines, patients are selected based upon Milan’s criteria that
includes HCC <5 cm or three nodules less than 3 cm each with no
microvascular invasion on imaging.55 The result of LT is dependent
on various factors such as tumor burden, ischemia time during
surgery, and use of immunosuppressive drugs. 56,57 Shortage of
organ availability is the main limiting factor resulting in candidates
being dropped out from the waiting list. Although associated with
higher postoperative morbidity and early mortality, LT delivers an
excellent 5-year OS rate of >70%.58-60 The recurrence rates are low,
approximately 10 to 18%.61,62 The practice of liver transplantation
continues to evolve with the promotion of live organ donation.

Ablation
Patients with stage 0-A disease, unsuitable for surgery due
to elevated portal pressure, anatomic location of tumor, or
comorbidities, should undergo ablation. Ablation is a minimally
invasive approach that may use RFA, MWA, alcohol, laser, or

34

cryotherapy. The basic underlying mechanism is alteration of
temperature leading to tumor necrosis. RFA is considered the
first line therapy63 and is recommended by both EASL and APASL.
Complications may be intra-abdominal hemorrhage, liver failure,
infection, tumor seeding, or biliary tract injury.64 It is a very safe
procedure with <0.5% mortality.65 Limitations include location of
tumor close to vessels, gallbladder, stomach, colon, or any other
viscera.66 The 5-year OS and recurrence rates of RFA are very similar
to that of LR.67
Microwave ablation (MWA) is a novel approach that has shown
outstanding results in the management of HCC. It offers similar
advantages as that of RFA as well as several other benefits like higher
degree of tumor necrosis, ability to treat larger tumors, reduced
procedure time, and feasibility to perform in tumors located close
to viscera or biliary tree.68 According to the available literature, there
is no statistically significant difference in efficacy and complication
rates between MWA and RFA.69-71 A recent RCT also endorsed
non-inferiority of MWA in terms of safety and local recurrence.72

Noncurative Therapy
For patients who are not eligible for curative treatments, several
other therapies are advocated to decrease tumor burden and
to prolong long-term survival. These include both palliative
interventions and systemic therapies.

Locoregional Therapy
Transarterial Chemoembolization
The vascular supply of HCC is derived from the hepatic artery, while
the rest of the liver parenchyma is supplied mainly by the portal
vein. This difference in vascular supply is the basic principle of
all embolization therapies as devascularization of tumor tissue is
acquired without affecting normal tissue. This is achieved via drugs,
embolic, or radioactive particles.73 Guidelines have recommended
transarterial chemoembolization (TACE) as the standard option for
patients with HCC of BCLC stage B as it has shown great survival
benefit.74-76
Conventional-TACE (cTACE) uses injection of chemotherapeutic
agents, such as doxorubicin, cisplatin, or mitomycin, mixed with
lipoidol into hepatic artery and completely obstructing it with
gelatin sponge, thus inducing ischemia and cytotoxicity leading
to tumor necrosis.77 Patients with portal vein thrombosis or
extrahepatic disease, high localized tumor burden (>10 cm), or
eGFR <30 mL/minute are not considered good candidates for
the procedure.73-79 Postembolization syndrome is a frequently
occurring complication, characterized by fever, abdominal pain,
nausea, and vomiting. It is usually mild and responds well to
antipyretic and analgesic therapy.80
TACE with drug-eluting beads (DEB-TACE) is a modified
version of conventional TACE in which polyvinyl alcohol hydrogel
is used to seal off the artery. This causes a sustained release of
chemotherapeutic drugs thus increasing cytotoxicity to tumor
cells while reducing exposure to rest of the hepatic parenchyma
and circulatory system.81,82 It is a better-tolerated procedure with
improved results and less severe adverse events eventhough the
rate of complications remains same as cTACE. The 5-year OS is
reported to be 18 to 28.7 months with cTACE and 30 to 40 months
with DEB-TACE. 76,83 DEB-TACE is not considered superior
to cTACE.84
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TACE with degradable starch microspheres (DSM-TACE) is a
novel technique that uses a completely degradable, hydrophilic
starch matrix that is able to reach at arteriolar or capillary level due
to its small diameter causing transient occlusion of small arteries.
This limited-time occlusion reduces the chances of systemic toxicity
and postembolization syndrome.85 Some studies have shown its
potential safety and efficacy proposing it as a second-line liverdirected therapy for patients with intermediate- to advanced-stage
HCC.86,87 A prospective study showed a median OS of 36 months
after DSM-TACE but randomized control trials are needed to validate
these results.

SBRT include location of tumor near important organs like biliary
tree or gastrointestinal tract increasing the risk of radiation induced
inflammation and bleeding. Radiation induced liver disease, defined
as hepatomegaly, ascites, and cholestasis, is a known complication
of SBRT which can be fatal in 5 to 13% cases.96,97 According to a
recent meta-analysis and a phase 2 clinical trial, the local control of
HCC achieved by SBRT is equivalent to that of RFA.98,99 Studies have
exhibited a median overall survival of 8 to 17 months after SBRT.100
However, there is still a paucity of data on long term survival beyond
2 years. No progression of disease was seen upto 1 to 3 years in 87
to 100% of cases.101

Transarterial Radioembolization

Systemic Therapy

Transarterial radioembolization (TARE), a form of selective internal
radiation therapy, is a highly advanced liver-directed therapy, that
uses intra-arterial injection of radioactive spheres (loaded with
Yttrium-90, iodine-131, or rhenium-188) to cause radiation-induced
tumor necrosis. 88 The magnitude of ischemia is comparatively
lesser in comparison to TACE, hence decreasing the chances and
severity of postembolization syndrome. It is indicated for BCLC-B
disease and unlike other radiological procedures, this intervention
can also be done in patients with portal vein thrombosis or high
tumor burden (bilobar disease). Patients not amenable to TARE
are the ones with metastatic HCC, decompensated cirrhosis,
prior radiation to liver, and significant hepatoenteric and
hepatopulmonary shunts (>20%).89 Postprocedure complications
include liver failure, radiation pneumonitis, biliary complications,
radioembolization induced liver disease, and postembolization
syndrome.90 The survival benefit is not reported to be very different
from TACE ranging from 14 to 16.9 months, but TARE demonstrated
reduced toxicity and longer time to progression of disease (13.3 vs
8.4 months).91,92

Systemic therapy is the cornerstone of treatment for patients with
advanced disease who are not surgical candidates or fit for liver
directed therapies. Over the past couple of years, systemic therapy
has immensely evolved, with multiple new drugs being approved
while others are under evaluation. Figure 1 shows currently available
drugs for systemic therapy.

Stereotactic Body Radiation
Historically, radiation therapy has never been a part of treatment
algorithms in HCC. However, enormous technological developments
over the last few decades have led to the introduction of stereotactic
body radiation therapy (SBRT) as a promising treatment for HCC.
It has been added to the NCCN guidelines for the treatment of
patients with nonresectable tumors with portal vein thrombosis
or extrahepatic metastases.93 A recent clinical audit showed
excellent results of SBRT in terms of safety and efficacy for large
inoperable HCCs.94 It has also shown great benefits in palliation of
symptomatic patients with metastatic lesions.95 The limitations to

Multikinase Inhibitors
These drugs exert antiproliferative, antiangiogenic and apoptotic
properties by blocking RAF signaling along with VEGF, platelet
growth factor and KIT.

First-line Therapy
Sorafenib
Sorafenib remained the only standard of care for patients with
BCLC-C disease, since its approval in 2007. Although it was first
discovered in 1990 but only gained FDA approval after the phase
3 sorafenib HCC assessment randomized protocol trial that proved
an increase in OS when compared with placebo (median OS 10.7
vs 7.9 months, respectively) in patients with advanced HCC.102 The
trial also indicated that sorafenib was potentially effective against
HCC regardless of tumor burden, ECOG class, liver status, AFP
levels, or previous therapy.103,104 The reported time to radiologic
progression was 5.5 months with sorafenib vs 2.8 months with
placebo. However, the overall response rate (ORR) was low.
Commonly encountered side effects were diarrhea, weight loss,
arterial hypertension, fatigue, and hand-foot syndrome. Around
30% patients do not tolerate sorafenib due to the side effects.
Improved outcomes were observed in patients who developed
dermatological side effects.105

Fig. 1: Systemic therapy for HCC
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Lenvatinib

Bevacizumab

Lenvatinib is another oral tyrosine kinase inhibitor that acts on
VEGFR 1 to 3, FGFR 1-4. RET, KIT, and PDGFR alpha. Its ability to inhibit
fibroblast growth factor receptors distinguishes it from sorafenib.
Lenvatinib gained approval as first-line therapy for advanced HCC
in 2018 on the basis of phase 3 REFLECT trial. The study included
unresectable HCC, BCLC-B and C patients with no prior systemic
therapy, and patients with greater than 50% liver impairment
and portal or biliary invasion were excluded. The results affirmed
non-inferiority of lenvatinib to sorafenib in terms of median OS
(13.6 vs 12.3 months, respectively). Lenvatinib also demonstrated
longer progression-free survival (7.3 vs 3.6 months), time for tumor
progression (7.4 vs 3.7 months), and higher objective response
rate (18.8 vs 6.5%) as well as better outcome in patients with AFP
greater than 200 ng/mL. Adverse event profile was similar to that
of sorafenib.106

It has recently been approved by FDA to be utilized as a combination
drug with atezolizumab against advanced HCC.

Donafenib
Donafenib is a novel multikinase inhibitor that has revealed great
anti-tumor activity and favorable tolerability. An open label,
randomized, phase 2/3 clinical trial from China demonstrated
significantly longer OS with donafenib compared to sorafenib
(12.1 vs 10.2 months, respectively). Frequent adverse events with
donafenib were hand-foot skin reaction, deranged liver functions,
thrombocytopenia, and diarrhea.107 Donafenib is currently pending
approval by the FDA.

Second-line Therapy
Regorafenib
Regorafenib was the first drug that showed survival benefit as
second-line treatment and was approved by FDA in 2017, after
the results of a phase 3 trial (RESOURCE) which showed significant
improvement in OS 10.6 vs 7.8 months with placebo, for patients
who had disease progression on sorafenib. It is also a multikinase
inhibitor with more profound antiangiogenic activity as it blocks
both VEGF and TIE pathways. Mostly encountered side effects were
hypertension, diarrhea, fatigue, and hand-foot reaction.108

Cabozantinib
Cabozantinib is a multikinase inhibitor that has stronger activity
against MET and AXL signaling pathways. The approval of
cabozantinib was based on a phase 3 trial (CELESTIAL) that
evaluated its efficacy in patients who progressed on or did not
tolerate sorafenib. The study demonstrated improved median OS
(10.2 vs 8.0 months), progression-free survival (5.2 vs 1.9 months),
and objective response rate (4 vs 1%). Adverse events commonly
noted were palmar-plantar erythrodysesthesia, hypertension,
fatigue, and diarrhea.109

Anti-VEGF Antibodies
Ramucirumab
Ramucirumab is a monoclonal recombinant IgG1 antibody
against VEGFR-2. A phase 3 study REACH-2 examined its action in
patients with advanced HCC with AFP levels greater than 400 ng/
mL. The results were improved median OS (8.5 vs 7.3 months),
progression-free survival (2.8 vs 1.6 months), and objective
response rate (5 vs 1%).110 Ramucirumab received FDA approval
as second-line agent against advanced HCC in May 2020.
36

Immunotherapy
Immunotherapy consists of immune checkpoint inhibitors that
have the potential to target checkpoint proteins on immune
and cancer cells. It is broadly classified, according to their target
immune cells, into three types, programmed cell death protein-1
(PD-1), programmed cell death 1 ligand 1 (PDL-1), and cytotoxic
T-lymphocyte associated protein 4 (CTLA-4) antibodies.

Nivolumab
Nivolumab is a monoclonal antibody that blocks PD1-receptor. It
gained accelerated approval as second-line therapy in 2017 based
on a phase 2 study (CheckMate 040). Later, the phase 3 study
(CheckMate 459) demonstrated the efficacy and safety of nivolumab
in patients with advanced HCC who failed sorafenib therapy.
According to the trial, the median OS was 16.4 vs 14.7 months
with placebo, progression-free survival was 3.7 vs 3.8 months, and
ORR was 20%. Fewer adverse effects were encountered compared
to sorafenib which included rash, elevated liver and pancreatic
enzymes, and pruritis.111

Pembrolizumab
On the basis of a phase 2 clinical trial, KEYNOTE-224, pembrolizumab
received accelerated FDA approval in 2018. The study compared
pembrolizumab with best supportive care in patients who
developed progression on sorafenib and demonstrated improved
median OS of 12.9 vs 10.6 months in the control group, progressionfree survival 4.9 vs 2.0 months, and ORR of 17%. Side effects were
similar to that of nivolumab and tolerated well.

Combination Therapy
The IMbrave150 is considered a breakthrough study as it leads to the
approval of the first combination therapy for HCC, simultaneously
paving the way for further advancements in this field giving a ray
of hope to the patients of HCC. Combination therapy is a field of
continuous medical expansion, multiple trials using different drug
combinations are ongoing and their outcomes are intently awaited.

Atezolizumab + Bevacizumab
This combination was approved in May 2020 as the first-line therapy
against advanced HCC, bringing a revolution to HCC therapy with
the idea that synergistic anti-tumor activity exerted by two drugs
can be superior to single-drug therapy. The study (IMbrave150)
compared combination of atezolizumab (PDL-1 inhibitor) and
bevacizumab (anti-VEGF antibody) with sorafenib in patients with
locally advanced or metastatic HCC. Results of the trial showed
progression-free survival of 6.8 vs 4.3 months with sorafenib and
ORR of 27.3 vs 11.9%, respectively. Commonly reported adverse
effects with the combination are hypertension, hepatitis, fever,
and proteinuria.112

Nivolumab + Ipilimumab
Nivolumab is a PD-1 inhibitor and ipilimumab is a CTLA-4 inhibitor
and their combination gained accelerated approval in 2020. The
trial CheckMate 040 reported an ORR of 31% and 24 months OS
rate was 40%. Adverse events included fatigue, diarrhea, rash,
pruritis, dyspnea, weight loss, abdominal pain, headache, arthralgia,
vomiting, and musculoskeletal pain.113
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Other Potential Combination Therapies
The concept of combination therapies is rapidly accelerating
as agents from different groups are being investigated for their
potential activity against HCC. LEAP-002 is studying the effects of
lenvatinib and pembrolizumab in advanced HCC.114 Combination
therapy with durvalumab and tremelimumab is also underway.115
Provisional results from a phase 2 study of camrelizumab plus
FOLFOX look promising.116 The possibilities are endless, hence
a good number of combination therapies are undergoing trials
currently (Table 2).

Genomic Therapy
The paucity of treatment options for HCC patients has stimulated
the researchers to look into all possibilities that can potentially
provide beneficial results. Genetic mutations associated with HCC
are currently being studied in depth with the idea of targeting
these specific mutations.117 Epigenetic alterations induced by
DNA methylation seem to be reversible, thus presenting a possible
target against which therapeutic strategies can be developed. DNA
methylation inhibitors, azacytidine, and decitabine are currently
being studied for HCC. A phase 1/2 trial conducted on decitabine
showed favorable results.118 A phase 2 trial using a combination
of guadecitabine, sorafenib, and oxaliplatin is currently ongoing
(NCT03257761).119
The dysregulation of histones is also under active investigation,
and drugs to modify their course are underway. Histone deacetylase
inhibitors, such as belinostat and resminostat, are under trial.
(NCT00321594, NCT00943449 ) Needless to say, it is only the tip of
the iceberg and provides a future landscape in the treatment of
HCC. It is expected that advancements in this field could lead to
the development of revolutionary therapies with the best possible
outcomes.

C o n c lu s i o n
HCC is a universal health burden due to the rapidly rising mortality
rate associated with it. According to the latest numbers, it is
estimated that its incidence will continue to grow. It is crucial to
devise therapeutic strategies that could control the disease and
prolong the survival of patients. Fortunately, systemic therapy has
advanced rapidly over the past few years. However, the advent
of immunotherapy has proven to be a game changer. The role of
genomic and adoptive cell therapy is still unclear. A lot of in-depth
research is therefore needed to further enhance our perception of
the disease at molecular and genetic levels, in order to explore new
treatment options for HCC.
Table 2: Ongoing trials on combination therapies for HCC
Sl. No
1
2
3
4
5
6
7

Combination
Lenvatinib + pembrolizumab
Durvalumab + tremelizumab
Nivolumab + ipilimumab
Cabozantinib + atezolimumab
Sintilimab + IBI305
Camrelizumab
SHR-1210 + apatinib
SBRT + Camrelizumab + apatinib

Trial number
NCT03713593
NCT03298451(HIMALAYA)
NCT01658878
NCT03755791(COSMIC-312)
NCT04072679
NCT02942329
ChiCTR1900027102

Orcid
Hasan Ozkan https://orcid.org/0000-0002-5203-2528
Wasim Jafri https://orcid.org/0000-0002-8902-2761
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